Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01670500 |
|
Recruitment Status :
Recruiting
First Posted : August 22, 2012
Last Update Posted : September 5, 2018
|
Sponsor:
Beth Israel Deaconess Medical Center
Information provided by (Responsible Party):
Nadine Tung, MD, Dana-Farber Cancer Institute
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | October 2021 |
| Estimated Study Completion Date : | October 2021 |